Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.

The advent of pathotropic (disease-seeking) targeting technologies, combined with advanced gene delivery vectors, provides a unique opportunity for the systemic delivery of immunomodulatory cytokine genes to remote sites of cancer metastasis. When injected intravenously, such pathotropic nanoparticles seek out and accumulate selectively at sites of tumor invasion and neo-angiogenesis, resulting in enhanced gene delivery, and thus cytokine production, within the tumor nodules. Used in conjunction with a primary tumoricidal agent (e.g., Rexin-G) that exposes tumor neoantigens, the tumor-targeted immunotherapy vector is intended to promote the recruitment and activation of host immune cells into the metastastic site(s), thereby initiating cancer immunization in situ. In this study, we examine the feasibility of cytokine gene delivery to cancerous lesions in vivo using intravenously administered pathotropically targeted nanoparticles bearing the gene encoding granulocyte/macrophage colony-stimulating factor (GM-CSF; i.e., Reximmune-C). In vitro, transduction of target cancer cells with Reximmune-C resulted in the quantitative production of bioactive and immunoreactive GM-CSF protein. In tumor-bearing nude mice, intravenous infusions of Reximmune-C-induced GM-CSF production by transduced cancer cells and paracrine secretion of the cytokine within the tumor nodules, which promoted the recruitment of host mononuclear cells, including CD40+ B cells and CD86+ dendritic cells, into the tumors. With the first proofs of principle established in preclinical studies, we generated an optimized vector configuration for use in advanced clinical trial designs, and extended the feasibility studies to the clinic. Targeted delivery and localized expression of the GM-CSF transgene was confirmed in a patient with metastatic cancer, as was the recruitment of significant tumor-infiltrating lymphocytes (TILs). Taken together, these studies provide the first demonstrations of cytokine gene delivery to cancerous lesions following intravenous administration and extend the applications of cancer immunization in vivo.

[1]  F. Hall,et al.  Phase I study of sequential targeted gene delivery: Intravenous infusions of Rexin-G followed by Reximmune-C induce tumor necrosis and recruitment of tumor infiltrating lymphocytes in cancerous lesions , 2008 .

[2]  E. Waller.  The role of sargramostim (rhGM-CSF) as immunotherapy. , 2007, The oncologist.

[3]  Yong Zhang,et al.  Liposomes, Dendrimers and other Polymeric Nanoparticles for Targeted Delivery of Anticancer Agents – A Comparative Study , 2007 .

[4]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[5]  F. Hall,et al.  Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. , 2007, International journal of oncology.

[6]  M. Santinami,et al.  Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. , 2006, Annals of Oncology.

[7]  L. Young,et al.  Viral gene therapy strategies: from basic science to clinical application , 2006, The Journal of pathology.

[8]  R. Rosenthal,et al.  Clinical applications of recombinant virus-based cancer immunotherapy , 2005, Expert opinion on biological therapy.

[9]  J. Nemunaitis,et al.  GM-CSF gene-transduced tumor vaccines. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  M. Weitzman,et al.  Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.

[11]  F. Hall,et al.  Nanotechnology blooms, at last (Review). , 2005, Oncology reports.

[12]  H. Mellstedt,et al.  Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor , 2004, Clinical Cancer Research.

[13]  Ding‐Shinn Chen,et al.  Curative potential of GM-CSF-secreting tumor cell vaccines on established orthotopic liver tumors: mechanisms for the superior antitumor activity of live tumor cell vaccines. , 2004, Journal of biomedical science.

[14]  D. Neuberg,et al.  Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jun-Tae Lee,et al.  Construction of a retroviral vector production system with the minimum possibility of a homologous recombination , 2003, Gene Therapy.

[16]  M. Etcheverrigaray,et al.  Choice of the adequate quantification method for recombinant human GM-CSF produced in different host systems , 2002 .

[17]  W. Anderson,et al.  Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver. , 2002, Human gene therapy.

[18]  W. Anderson,et al.  Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. , 2001, International journal of molecular medicine.

[19]  S. Groshen,et al.  Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. , 2001, Human gene therapy.

[20]  S. Groshen,et al.  Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. , 2000, Cancer research.

[21]  Jungkon Kim,et al.  High efficiency retroviral vectors that contain no viral coding sequences , 2000, Gene Therapy.

[22]  R. Beart,et al.  Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. , 2000, Human gene therapy.

[23]  G. Weiner,et al.  Uses of granulocyte-macrophage colony-stimulating factor in vaccine development , 2000, Current opinion in hematology.

[24]  M. Hitt,et al.  Gene vectors for cytokine expression in vivo. , 2000, Current pharmaceutical design.

[25]  A. Chalian,et al.  Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. , 2000, Human gene therapy.

[26]  K. Peng,et al.  Viral vector targeting. , 1999, Current opinion in biotechnology.

[27]  E. Sotomayor,et al.  A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. , 1999, Human gene therapy.

[28]  T. Dubensky,et al.  The Resistance of Retroviral Vectors Produced from Human Cells to Serum Inactivation In Vivo and In Vitro Is Primate Species Dependent , 1999, Journal of Virology.

[29]  J. Fagerberg,et al.  Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. , 1999, Current opinion in hematology.

[30]  W. Anderson,et al.  Identification of the block in targeted retroviral-mediated gene transfer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Kielian,et al.  Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice , 1998, Cancer Immunology, Immunotherapy.

[32]  C. An,et al.  Construction of Retroviral Vectors with Improved Safety, Gene Expression, and Versatility , 1998, Journal of Virology.

[33]  W. Anderson,et al.  Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. , 1997, Human gene therapy.

[34]  J. Krauss,et al.  Cytokines as an adjuvant to tumor vaccines: Efficacy of local methods of delivery , 1997, Annals of Surgical Oncology.

[35]  C. Wysocki,et al.  Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. , 1996, Human gene therapy.

[36]  W. Anderson,et al.  Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. , 1995, Cancer research.

[37]  F. Cosset,et al.  Retroviral retargeting by envelopes expressing an N-terminal binding domain , 1995, Journal of virology.

[38]  A. Kingsman,et al.  A transient three-plasmid expression system for the production of high titer retroviral vectors. , 1995, Nucleic acids research.

[39]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[40]  T. Chou,et al.  IMMUNOTHERAPY OF CANCER , 1971, Advances in Cancer Research.

[41]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[42]  F. Hall,et al.  First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. , 2004, International journal of oncology.

[43]  P. Sheridan,et al.  The use and development of retroviral vectors to deliver cytokine genes for cancer therapy. , 2000, Critical reviews in therapeutic drug carrier systems.

[44]  M. Choti,et al.  Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. , 1999, Journal of surgical oncology.

[45]  A. Miller,et al.  Improved retroviral vectors for gene transfer and expression. , 1989, BioTechniques.

[46]  F. Hall,et al.  Pathotropic nanoparticles for cancer gene therapy , 2022 .